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Abstract Misfolded or unassembled secretory proteins are
retained in the endoplasmic reticulum (ER) and subsequently
degraded by the cytosolic ubiquitin-proteasome system. This
requires their retrograde transport from the ER lumen into the
cytosol, which is mediated by the Sec61 translocon. It had
remained a mystery whether ER-localised soluble proteins are at
all capable of re-entering the Sec61 channel de novo or whether a
permanent contact of the imported protein with the translocon is
a prerequisite for retrograde transport. In this study we analysed
two new variants of the mutated yeast carboxypeptidase yscY,
CPY*: a carboxy-terminal fusion protein of CPY* and pig liver
esterase and a CPY* species carrying an additional glycosylation
site at its carboxy-terminus. With these constructs it can be
demonstrated that the newly synthesised CPY* chain is not
retained in the translocation channel but reaches its ER lumenal
side completely. Our data indicate that the Sec61 channel
provides the essential pore for protein transport through the ER
membrane in either direction; persistent contact with the
translocon after import seems not to be required for retrograde
transport.
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1. Introduction
In eukaryotic cells all secretory proteins enter the endoplas-
mic reticulum (ER), where they are folded prior to their fur-
ther transport through the secretory system [1,2]. Since the ER
has to guarantee the delivery of only properly folded proteins,
it contains a quality control system to proofread and eliminate
inactive proteins. Misfolded or unassembled proteins in the
ER lumen or the ER membrane are rapidly degraded by the
cytosolic ubiquitin proteasome machinery [3^5]. This process,
known as ER-associated degradation, requires the retrograde
translocation of the substrate molecules from the ER back to
the cytosol prior to their hydrolysis [3^5]. Central components
of the Sec61 translocon, identi¢ed as the highly conserved
channel for protein import into the ER in eukaryotic cells
[2], have been described to mediate this retrograde transport
[6^8]. For membrane proteins the retrograde transport mech-
anism through lateral gating into the Sec61 channel and ex-
traction is conceptually easy to envisage [6,9]. For soluble,
lumenal proteins of the ER di¡erent mechanisms seem possi-
ble: already during translocation a not properly foldable pro-
tein is recognised as such, translocation is arrested, leaving
permanent contact with the Sec61 translocon and thereafter
its retrograde transport is initiated. Alternatively, the protein
leaves the translocon and is completely translocated into the
ER lumen, where it is recognised as being misfolded. The
latter mechanism would imply a re-targeting mechanism to
the translocon for retrograde protein transport.
In this study we wanted to address the question of whether
ER-localised soluble proteins like CPY*, a misfolded protein
that undergoes retrograde transport from the ER lumen to the
cytosol [7], are indeed capable of entering the Sec61 channel
from the lumenal side de novo or whether physical contact
with the translocon has to be maintained for retrograde trans-
port and cytosolic degradation to occur. Therefore, we gen-
erated two CPY* derivatives, one carrying a carboxy-terminal
fusion protein, the second having a ¢fth glycosylation site at
the carboxy-terminus that would function as a tool to monitor
persistent contact of the nascent chain with the translocon or
complete import into the ER lumen.
2. Materials and methods
2.1. Construction of yeast strains and plasmids
Genetic experiments and molecular biological methods were carried
out using standard protocols [10]. Yeast strains used in this study are
summarised in Table 1.
For generating CPY* derivatives, a 2258 bp ClaI/HpaI fragment
of plasmid bMK150, vector pRS306 [11] containing the prc1-1 allele,
was cloned into a ClaI/SmaI-linearised pRS313 vector [11] yielding
plasmid bRP312. For the carboxy-terminal fusion of pig liver esterase
(PLE) to CPY* an AatII site upstream of the PLE gene and a
SpeI site downstream of the PLE gene were introduced by PCR
using as primers 5P-CCATTTGACGTCGGGCAGCCAGCCTCG-
CCG-3P and 5P-GTCAGACTAGTTCACAGCTCAGCATGCTTTA-
TC-3P. The plasmid containing the PLE gene was a gift of U. Born-
scheuer, Stuttgart. The PCR product was cloned into the AatII/SpeI-
linearised vector bRP312 after AatII/SpeI digestion resulting in plas-
mid prc1-PLE. To introduce the sequence encoding a ¢fth glycosyla-
tion site into the prc1-1 allele a recombinant PCR strategy was
used. Primer sequences were 5P-TGTGAAGGTGGCAATTTGTGC-
3P and 5P-CGCTTTATAAAGTACTATTGGAGAAACCACCGTG-
GATCCATTCG-3P for PCR I and 5P-CTGGGGTTCTTTGATT-
GGGG-3P and 5P-CGGTGGTTTCTCCAATAGTACTTTATAAA-
GCGTGTATGTGTAGGC-3P for PCR II. The PCR products and
the two short primers were used in a third reaction to yield a 970 bp
product that was con¢rmed by DNA sequencing. For generation of
plasmid prc1-G5 plasmid bRP312 was linearised with NotI, treated
with Klenow enzyme, digested with AatII, and ligated with a 404 bp
AatII/PvuII fragment of the ¢nal PCR reaction. vprc1 deletion strains
were generated by transforming yeast strains W303-1B and YRP086
with the KspI/BglII-digested plasmid CPY-ko, which was a gift of G.
Polhig, Basel. Knockouts were con¢rmed by CPY activity tests and
Western analysis using CPY-speci¢c antiserum.
2.2. Immunodetection
Cells were grown in complete synthetic medium (CM) containing
2% glucose to an OD600 of 1.5. For Western analysis the equivalent of
3 OD600/ml of cells were taken and subjected to alkaline lysis and
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trichloroacetic acid (TCA) precipitation as described [7]. Precipitates
were incubated in sample bu¡er (8 M urea, 200 mM Tris-HCl, pH 6.8,
5% SDS, 0.1 mM EDTA, 0.03% bromophenol blue, 1.5% DTT) at
45‡C for 30 min with vigorous agitation and separated on 8% SDS-
polyacrylamide gels. Proteins on immunoblots were visualised by en-
hanced chemoluminescence detection (ECL, Amersham) according to
the manufacturer’s instructions.
2.3. Protease protection experiments
Cells were grown as previously described. After spheroblasting the
equivalent of 50 OD600/ml of cells [7] these were gently lysed using a
tissue grinder. The lysate was cleared of remaining cells and debris by
repeated centrifugation for 5 min at 3000Ug. The cleared lysate was
split into aliquots corresponding to 12.5 OD600/ml. From the time of
lysis, all material was kept on ice. Separation of membranes was done
by a 30 min centrifugation at 20 000Ug at 4‡C. For protease treat-
ment of the pellet trypsin was added at a ¢nal concentration of 0.5 mg/
ml after resuspension of the pellet and the samples were incubated for
30 min on ice. If added, Triton X-100 was present at 1%. All treat-
ments were stopped by adding TCA with a ¢nal concentration of
10%. After resuspending the pellet in sample bu¡er at 45‡C for
45 min proteins were analysed by SDS-PAGE and immunoblotting.
2.4. Deglycosylation experiments
Cells were grown to an OD600 of 2 followed by immunoprecipita-
tion and deglycosylation as described [7]. Brie£y, the equivalent of
10 OD600/ml of cells were subjected to alkaline lysis, immunoprecipi-
tation of CPY*, and treatment with 0.06 U endoglycosidase F for 1 h
at 37‡C. Finally, the samples were resuspended in urea bu¡er and
analysed by SDS-PAGE and immunoblotting.
2.5. Tunicamycin treatment
Cells were grown as described to an OD600 of 1.0 and the equivalent
of 10 OD600/ml of cells were taken for each sample. Cells were labelled
with 25 WCi [35S]methionine for 30 min at 37‡C in the absence or
presence of 10 Wg/ml, 20 Wg/ml, and 50 Wg/ml tunicamycin followed
by cell lysis and immunoprecipitation as described before. Proteins
were separated on SDS-polyacrylamide gels followed by £uorography.
2.6. Cycloheximide chase analysis
Cells were grown as described and then adjusted to approximately
8 OD600/ml. After adding cycloheximide to a ¢nal concentration of
0.1 mg/ml, 1 ml of cell suspension was removed at the indicated time
points, suspended in a sodium azide solution (¢nal concentration
10 mg/ml) and kept at 380‡C. Cell lysis, TCA precipitation, SDS-
PAGE, and immunodetection were performed as described before.
3. Results
3.1. Translocation of a carboxy-terminal fusion protein of
CPY* into the ER is not a¡ected by the ER quality control
system
Using a mutated carboxypeptidase yscY (CPY*), allele
prc1-1 [12,13], as a substrate we addressed the question
whether the translocation of CPY* into the ER lumen is com-
pleted or whether CPY* maintains permanent contact with
the translocon due to its recognition by the ER quality con-
trol system prior to retrograde transport for its proteasomal
degradation. Successful termination of CPY* import into the
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Table 1
Yeast strains used in this study
Strain Genotype Source
W303-1B MATK ura3-1 his3-11,15 leu2-3,112 trp1-1 ade2-1oc can1-100 [20]
W303-1C W303 prc1-1 [16]
W303-1C PLE W303 prc1-1 prc1-PLE This study
W303 vC W303 vprc1 : :LEU2 This study
W303-1C G5 W303 prc1-1 prc1-G5 This study
W303 vC G5 W303 vprc1 : :LEU2 prc1-G5 This study
YRP086 W303 sec61-2 prc1-1 [7]
YRP086 G5 W303 sec61-2 prc1-1 prc1-G5 This study
YRP086 vC G5 W303 sec61-2 vprc1 : :LEU2 prc1-G5 This study
W303-CD W303 vder1 : :URA3 prc1-1 [16]
W303-CD G5 W303 vder1 : :URA3 prc1-1 prc1-G5 This study
W303-CPQ W303 vubc6 : :LEU2 vubc7 : :LEU2 prc1-1 [15]
W303-CPQ G5 W303 vubc6 : :LEU2 vubc7 : :LEU2 prc1-1 prc1-G5 This study
Fig. 1. A fusion protein of CPY* and PLE is imported completely
into the ER. A: Scheme of the fusion construct. B: Western analy-
sis of yeast strain W303-1C PLE (prc1-1 prc1-PLE) carrying the
plasmid-encoded CPY*-PLE fusion protein and W303-1C (prc1-1).
C: Protease protection analysis of yeast strain W303-1C PLE (prc1-
1 prc1-PLE) after preparing spheroblast homogenates followed by a
20 000Ug centrifugation (S, supernatant; P, pellet fraction; P (T),
pellet treated with trypsin; P (T+T) pellet treated with trypsin and
Triton X-100). To con¢rm the integrity of the prepared vesicles
CPY* was analysed on the same membrane. For immunodetection
antibodies directed against CPY were used.
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Fig. 2. An additional glycosylation site at the carboxy-terminus of CPY* is recognised by the ER glycosylation machinery: evidence that the
entire protein is imported into the ER. A: An additional glycosylation side was introduced at the carboxy-terminus of CPY*. B: Western anal-
ysis of W303-1C G5 (prc1-1 prc1-G5) carrying the plasmid encoded PRC1-G5 allele, W303-1C (prc1-1), W303-1B (PRC1), and W303-vC
(vprc1 : :LEU2). C: Endoglycosidase F (EF) treatment of immunoprecipitates of W303-1C (prc1-1), W303-1C G5 (prc1-1 prc1-G5), and W303-
vC G5 (vprc1 : :LEU2 prc1-G5) cell lysates. D: Autoradiographic analysis of strain W303-1C G5 (prc1-1 prc1-G5) after incubation in the pres-
ence of increasing amounts of tunicamycin. E: The ¢vefold glycosylated CPY* species is still a substrate of the ER degradation system. Cyclo-
heximide chase analysis was performed in yeast strains W303-1C G5 (prc1-1 prc1-G5), W303-CD G5 (vder1 : :LEU2 prc1-G5), and W303-CPQ
G5 (vubc6 vubc7 prc1-G5) at 30‡C. After adding cycloheximide, aliquots of cells were lysed at each time point and TCA precipitates were sub-
jected to SDS-PAGE and immunoblotting using CPY-speci¢c antibodies.
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ER would subsequently require a re-targeting event back to
the Sec61 translocon followed by re-entering the channel from
the ER lumenal side de novo prior to its retrograde transport
and degradation. This would imply that opening of the trans-
location channel can be initiated from both sides of the ER
membrane, the cytosol and the lumen.
For this purpose we constructed and analysed two kinds of
CPY* mutants. We fused a PLE to the carboxy-terminus of
CPY* (Fig. 1A) resulting in a fusion protein of about 130 kDa
molecular mass (Fig. 1B). Cell extracts were prepared and
separated into a soluble and a microsomal fraction. When
treated with antibodies directed against CPY, the antigenic
material was exclusively found in the pellet fraction, indicat-
ing that its post-translational targeting to the ER membrane
after synthesis was una¡ected (Fig. 1C). Moreover, the entire
molecule including its carboxy-terminal PLE part was im-
ported into the ER lumen as could be demonstrated by pro-
tease treatment of intact microsome preparations (Fig. 1C).
We thus conclude that import of the CPY* chain into the ER
lumen is not blocked by the ER quality control system after
the full-length mutated CPY* molecule has appeared in the
lumen. We cannot exclude, however, that a stretch containing
about 20 amino acids of the carboxy-terminus of the fusion
protein is retained in the translocation channel. They could
escape degradation by trypsin because they are protected by
Sec61p.
3.2. The carboxy-terminus of CPY* reaches the ER lumen
Therefore, we generated another variant of CPY* (CPY*-
G5) carrying a ¢fth glycosylation site at the very end of the
carboxy-terminus in addition to the four glycosylation sites
present in CPY* (Fig. 2A). Only after completion of protein
import into the ER this additional glycosylation site would be
recognised by the ER glycosylation machinery. Indeed, West-
ern analysis revealed an increased molecular weight of the
CPY*-G5 species as compared to the authentic fourfold gly-
cosylated CPY* suggesting glycosylation at all ¢ve sites (Fig.
2B). Treatment with endoglycosidase F and tunicamycin con-
¢rmed that the increased molecular mass of the CPY*-G5
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Fig. 3. The sec61-2 mutation does not a¡ect termination of CPY*
import into the ER. A: Western analysis of yeast strains YRP086
vC G5 (sec61-2 vprc1 : :LEU2 prc1-G5) and W303-vC G5
(vprc1 : :LEU2 prc1-G5) after incubation at 25‡C. No translocation
intermediate with only four or fewer glycosylation chains could be
detected. B: Degradation but not import of CPY* and CPY*-G5 is
retarded in sec61-2 mutant cells at 25‡C. Cycloheximide chase anal-
ysis of yeast strains YRP086 G5 (sec61-2 prc1-1 prc1-G5) G5),
W303-1C G5 (prc1-1 prc1-G5) was performed as described in Fig.
2D.
Fig. 4. Schematic representation of three di¡erent scenarios conceivable as a basis for retrograde transport of CPY* by the Sec61 channel: per-
manent physical contact (A/B) or de novo re-entering (C).
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species was due to glycosylation and not to the altered amino
acid sequence at the carboxy-terminus of the molecule (Fig.
2C,D). This experiment demonstrated full translocation of the
CPY*-G5 molecule through the Sec61 channel.
Since it had been reported previously that a completely
unglycosylated CPY* variant remains stable in the ER lumen
[14], it was important to demonstrate that the degradation
process of CPY*-G5 was una¡ected by the additional carbo-
hydrate chain. Degradation of CPY* by the proteasome de-
pends on ER membrane proteins as Der1p and the ubiquitin
conjugating enzymes Ubc6p and Ubc7p. We therefore deter-
mined the degradation kinetics of CPY*-G5 as compared to
CPY* in wild type cells and in cells carrying mutations which
a¡ect the degradation process as vder1 and vubc6/ubc7 [15,16]
(Fig. 2E). In wild type cells, the half-life of CPY*-G5 was
almost identical to CPY*. Moreover, degradation of CPY*-
G5 was also dependent on Der1p and Ubc6/Ubc7 (Fig. 2E)
suggesting that this CPY* species is still a substrate of the ER
degradation system.
3.3. The sec61-2 mutation does not a¡ect the termination of
CPY* import into the ER
Mutant strains carrying the temperature sensitive sec61-2
allele, which causes rapid degradation of unassembled
Sec61-2p molecules at the restrictive temperature of 37‡C
[17], are defective in retrograde transport of CPY* and of a
mutated ABC transporter Pdr5 (Pdr5*) at 25‡C [7,9]. To fur-
ther exclude the possibility that also the termination of pro-
tein translocation into the ER lumen is a¡ected by the sec61-2
mutation, we analysed the fate of the CPY*-G5 protein in
yeast cells carrying the sec61-2 allele (Fig. 3A). We observed
no translocation intermediates of CPY*-G5 carrying less than
¢ve carbohydrate chains in sec61-2 mutant cells. This demon-
strates that once initiated import of CPY*-G5 into the ER
lumen goes to completion both in wild type and in sec61-2
mutants. This ¢nding was con¢rmed by analysing the degra-
dation kinetics of CPY* and CPY*-G5 in wild type and
sec61-2 mutant cells at 25‡C (Fig. 3B). Consistent with pre-
vious results for CPY* the half-life of both CPY* species was
increased about threefold in sec61-2 mutant cells, indicating
that CPY* re-entering of the Sec61 channel and retrograde
transport is a¡ected by the sec61-2 mutation and not termi-
nation of protein import into the ER lumen.
4. Discussion
Using two di¡erent CPY* constructs, a carboxy-terminal
PLE fusion protein and a species carrying a ¢fth glycosylation
site at the carboxy-terminus, we were able to distinguish be-
tween three di¡erent scenarios conceivable for retrograde
transport of CPY*:
1. The ER quality control system recognises misfolding of
CPY* already at the state of import and prevents further
translocation. In this case the carboxy-terminus would
never reach the translocon. Thus the carboxy-terminally
attached PLE protein would remain cytosolic (Fig. 4A).
Protease treatment of isolated microsomes demonstrates
membrane protection of the entire CPY*-PLE fusion
protein and therefore argues against this possibility.
2. The ER quality control system recognises misfolding of
CPY* and prevents termination of translocation into the
ER. In this case the last about 20 amino acids would be
trapped in the translocon (Fig. 4B). Here, a glycosyla-
tion site at the very carboxy-terminus of CPY* would
not be recognised by the ER lumenal glycosylation ma-
chinery.
3. Termination of translocation of CPY* is not a¡ected by
the ER quality control system. Here, a glycosylation site
at the very carboxy-terminus of CPY* would be used by
the ER lumenal glycosylation machinery (Fig. 4C). Our
data support this latter possibility. The carboxy-termi-
nally introduced glycosylation site is recognised and a
¢fth carbohydrate chain is added onto the CPY* mole-
cule.
Our experiments indicate full translocation of CPY* to the
lumenal side of the ER membrane. We have thus to conclude
that CPY* is able to re-enter the Sec61 channel from the
lumenal side for retrograde transport and degradation to oc-
cur. This implies a novel ER-localised targeting machinery for
retrograde transport of misfolded proteins. Whether previ-
ously discovered components of the ER degradation system
such as Der1p [16], Der3p/Hrd1p [18,19], or Hrd3p [19] are
part of this machinery has to be shown in the future.
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